Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

PURPOSE: During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical tria...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovasc Drugs Ther
Hauptverfasser: Langslet, Gisle, Hovingh, G. Kees, Guyton, John R., Baccara-Dinet, Marie T., Letierce, Alexia, Manvelian, Garen, Farnier, Michel
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334259/
https://ncbi.nlm.nih.gov/pubmed/32363493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-020-06984-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge